The aberrant expression of non-coding RNA in both PKD1 and PKD2 patients provides new insight into the pathogenesis of ADPKD and represents promising biomarkers that can improve diagnostic performance and the evaluation of disease progression, as well as acting as a potential therapeutic target. This evidence concerns the gene PKD2 and autosomal dominant polycystic kidney disease.